Ovarian/Fallopian/Peritoneal

- Relapsed or Refractory intolerant to standard care
  - CCT5048
    - Phase 1 Open Label Dose Escalation Study of CRX100 in Advanced Solid Tumors
      - PI: Dorigo
      - BioEclipse Therapeutics
      - 1st Priority
  - GYNOVA0056
    - Phase IIb Single Arm Study of Maveropecimut-S and Low-Dose Cyclophosphamide in Platinum-Resistant, Epithelial Ovarian Cancer (AVALON)
      - PI: Dorigo
      - Sponsor: IMV Inc.
  - GYNOVA0053
    - Phase III AVB-56-500 in Combination with Paclitaxel in Platinum-Resistant Recurrent Ovarian Cancer
      - PI: Diver
      - Aravive Biologics, Inc.
  - VAR0211
    - Phase III/II FolateReceptor Alpha-Targeting Antibody-Drug Conjugate in Selected Tumor Types
      - PI: Berek
      - Eisai Inc.
      - 2nd Priority
  - GYNOVA0054
    - Phase III Alpelisib (BYL719) in Combination w/ Olaparib vs Chemotherapy in Platinum-Resistant or Refractory Ovarian Cancers
      - PI: Diver
      - Sponsor: Novartis Pharmaceuticals Corporation

KEY
- Pending
- Open for Enrollment
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu